Long Term Extension Trial of Setmelanotide

Completed · Phase 2/Phase 3

Conditions studied: Obesity Associated With Defects in Leptin-melanocortin Pathway

In brief

This was a long-term extension trial to study the safety and tolerability of continued setmelanotide treatment in participants who had completed a previous clinical trial on treatment with setmelanotide for obesity associated with genetic defects upstream of the Melanocortin-4 (MC4) receptor in the leptin-melanocortin pathway.

Key facts

Study ID
NCT03651765
Run by
Rhythm Pharmaceuticals, Inc.
People needed
205
Starts
2018-07-15
Expected to finish
2025-01-09
Last updated by the study team
2025-05-31

Who can join

Age: 2 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.